Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes

MLA

Piero Ruggenenti, et al. “Nephrotic-Range Proteinuria in Type 2 Diabetes: Effects of Empagliflozin on Kidney Disease Progression and Clinical Outcomes.” EClinicalMedicine, vol. 43, no. 101240-, Jan. 2022. EBSCOhost, https://doi.org/10.1016/j.eclinm.2021.101240.

APA

Piero Ruggenenti, Bettina J. Kraus, Silvio E. Inzucchi, Bernard Zinman, Stefan Hantel, Michaela Mattheus, Maximilian von Eynatten, Giuseppe Remuzzi, Audrey Koitka-Weber, & Christoph Wanner. (2022). Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes. EClinicalMedicine, 43(101240-). https://doi.org/10.1016/j.eclinm.2021.101240

Chicago

Piero Ruggenenti, Bettina J. Kraus, Silvio E. Inzucchi, Bernard Zinman, Stefan Hantel, Michaela Mattheus, Maximilian von Eynatten, Giuseppe Remuzzi, Audrey Koitka-Weber, and Christoph Wanner. 2022. “Nephrotic-Range Proteinuria in Type 2 Diabetes: Effects of Empagliflozin on Kidney Disease Progression and Clinical Outcomes.” EClinicalMedicine 43 (101240-). doi:10.1016/j.eclinm.2021.101240.